Hemophilia A Treatment Market to Grow with a CAGR of 6.01% through 2028
Rising advent of revolutionary gene therapies is expected
to drive the Global Hemophilia A Treatment Market growth in the forecast
period, 2024-2028.
According to TechSci Research report, “Hemophilia A
Treatment Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Hemophilia A Treatment Market
stood at USD 8.28 billion in 2022 and is anticipated to grow with a CAGR of 6.01%
in the forecast period, 2024-2028. Hemophilia A, a rare genetic bleeding
disorder characterized by a deficiency of clotting factor VIII, affects
individuals worldwide. The global Hemophilia A Treatment Market plays a pivotal
role in addressing the unique healthcare needs of these patients. One of the
primary drivers fueling the growth of the Hemophilia A Treatment Market is the
rising prevalence of the disorder. While Hemophilia A is considered rare, improved
awareness, genetic testing, and diagnostic capabilities have led to a higher
number of diagnosed cases. As more individuals are identified with Hemophilia
A, there is a growing demand for effective treatment options, creating a robust
market. Advances in genetic research have revolutionized our understanding of
Hemophilia A at the molecular level. This knowledge has paved the way for the
development of innovative therapies, including gene therapy. Gene therapy for
Hemophilia A holds tremendous promise as it aims to correct the underlying
genetic mutation responsible for the clotting factor deficiency. This novel
approach represents a significant driver in the market, offering the potential
for long-term solutions and reducing the need for frequent factor replacement
therapies. Traditionally, Hemophilia A treatment focused on replacing the
missing clotting factor VIII through intravenous infusions of plasma-derived or
recombinant factor concentrates. However, the market is experiencing a paradigm
shift towards non-factor replacement therapies. These include bypassing agents,
which help blood clot in the absence of factor VIII, and novel therapies that
aim to mimic or enhance the function of factor VIII. This shift reflects a
growing emphasis on improving patient outcomes and reducing the burden of
frequent infusions.
The competitive landscape of the Hemophilia A
Treatment Market is continually evolving, with pharmaceutical companies
striving to develop and market cutting-edge therapies. This competition has
resulted in an array of product offerings, including extended half-life factor
concentrates and innovative formulations that enhance the convenience and
effectiveness of treatment. This product innovation benefits patients by
providing more choices and improved treatment options. Gene therapy has emerged
as a game-changer in Hemophilia A treatment. Several promising gene therapy
candidates are in various stages of clinical development, and some have already
received regulatory approvals. These therapies aim to introduce functional
factor VIII genes into patients' cells, potentially offering a long-lasting or
even curative treatment option. The increasing investment in gene therapy
research and development by pharmaceutical companies is driving market growth
and transforming the treatment landscape.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Hemophilia A Treatment Market.”
Furthermore, Patients and advocacy groups play a
significant role in driving the Hemophilia A Treatment Market. Their efforts to
raise awareness, promote research, and advocate for improved access to
treatment have had a substantial impact. Patient-centric care models prioritize
the holistic well-being of individuals with Hemophilia A, and this approach is
increasingly influencing treatment decisions and healthcare policies.
The Global Hemophilia A Treatment Market is segmented
into treatment type, route of administration, Distribution channel, regional
distribution, and company.
Based on the Treatment Type, the Factor Replacement
Therapy segment emerged as the dominant player in the global market for Global
Hemophilia A Treatment Market in 2022. This is due to the well-established
history and widespread use of Factor Replacement Therapy as the primary
treatment approach for Hemophilia A. Factor Replacement Therapy can be tailored
to the individual needs of Hemophilia A patients. Dosing and treatment
frequency can be adjusted based on the severity of the condition, lifestyle
factors, and patient preferences, allowing for personalized care. Factor
Replacement Therapy has been the cornerstone of Hemophilia A treatment for
decades. Its effectiveness in managing bleeding episodes and preventing
complications such as joint damage is well-documented and widely recognized by
healthcare professionals and patients alike. Factor Replacement Therapy
provides rapid and reliable relief from bleeding episodes, making it the go-to
treatment in emergency situations. It has a strong track record of effectively
controlling bleeding, which has built trust among healthcare providers and
patients.
Based on the Distribution Channel, the hospital
pharmacies emerged as the dominant player in the global market for Global
Hemophilia A Treatment Market in 2022.
Hospital pharmacies typically have highly trained pharmacists and
healthcare professionals who specialize in Hemophilia A treatment. Their
expertise in dosing, preparation, and administration of clotting factor concentrates
ensures that patients receive safe and effective care. Hospitals often serve as
comprehensive Hemophilia Treatment Centers (HTCs) that provide a wide range of
services, including diagnosis, treatment, patient education, and psychosocial
support. These HTCs are integral to managing Hemophilia A, and hospital
pharmacies are a crucial component of these centers. Hemophilia A patients may
require urgent treatment for bleeding episodes. Hospital pharmacies are
well-equipped to respond to emergencies, ensuring that patients receive prompt
access to clotting factor concentrates to control bleeding effectively.
North America emerged as the dominant player in the
global Hemophilia A Treatment Market in
2022, holding the largest market share. This is on account of advanced
healthcare infrastructure, high disease prevalence and increased awareness in
the region. North America has a relatively high prevalence of Hemophilia A compared
to other regions. This higher disease burden necessitates a strong healthcare
system and a well-established market for Hemophilia A treatment. There is a
significant level of awareness about Hemophilia A in North America, both among
healthcare professionals and the general public. This heightened awareness
leads to earlier diagnoses, proactive treatment approaches, and better overall
management of the condition.
Major companies operating in Global Hemophilia A
Treatment Market are:
- Takeda Pharmaceutical Company Limited
- Sanofi Corporation
- Genentech USA, Inc.
- Novo Nordisk
- Pfizer Inc.
- CSL Behring LLC.
- Grifols
- Sagent Pharmaceuticals
- Octapharma USA Inc.
- UBI Pharma Inc.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Hemophilia A Treatment Market is poised for significant growth in the coming
years, driven by several key factors that are reshaping the landscape of care
for individuals with this rare genetic bleeding disorder. One of the primary
factors contributing to this anticipated growth is the emergence of
cutting-edge gene therapies. Gene therapy offers the potential for a
long-lasting or even curative treatment for Hemophilia. Furthermore, the market
is witnessing remarkable advancements in extended half-life factor
concentrates, which reduce the frequency of treatment infusions, improving
patient adherence and overall quality of life. The shift towards prophylactic
treatment, aimed at preventing bleeding episodes rather than treating them
reactively, is gaining momentum and proving to be a highly effective approach,
particularly in pediatric populations. Additionally, the Global Hemophilia A
Treatment Market benefits from increasing disease awareness and improved
diagnostic capabilities, leading to earlier and more accurate diagnoses. This,
in turn, drives the demand for innovative treatment options, contributing to
market growth..” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Hemophilia A Treatment Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By
Treatment Type (Factor Replacement Therapy, Non-Factor Replacement Therapies,
Gene Therapy),By Route of Administration (Intravenous, Oral, Nasal), By
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies) By Region and Competition”, has evaluated the future growth potential of Global
Hemophilia A Treatment Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Hemophilia
A Treatment Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Website:
www.techsciresearch.com